Physician profile
Jared B Gilman
NPI 1801240569
$40,208.13
in general payments reported to CMS, 2019-2025
27 companies · $2,062 in 2025
The $2,062 reported for 2025 was more than what 86% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $20K · 2021: $1,123 · 2022: $812 · 2023: $10K · 2024: $5,584 · 2025: $2,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,883 · Honoraria: $7,000 · Travel and Lodging: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,882.54 |
| Honoraria | $7,000.00 |
| Travel and Lodging | $1,136.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $15,496.37 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $7,549.06 | 2023 | Seglentis |
| Boston Scientific Corporation | $6,618.84 | 2020-2025 | Intracept, Bionic Navigator, Artisan |
| Nalu Medical, INC. | $4,041.87 | 2023-2025 | Nalu Neurostimulation System |
| Abbott Laboratories | $1,856.71 | 2021-2025 | Eterna, Proclaim, Octrode |
| Saluda Medical Americas, INC. | $1,165.75 | 2023-2025 | Evoke, Evoke Scs |
| Stryker Corporation | $818.50 | 2021-2024 | Ivas |
| Collegium Pharmaceutical, INC. | $727.66 | 2021-2025 | Xtampza, Belbuca |
| Vertos Medical, INC. | $509.09 | 2023-2024 | Mild Device Kit |
| Nevro Corp. | $414.91 | 2022-2024 | Senza |
| Spr Therapeutics, INC | $233.72 | 2024-2025 | Sprint Pns System |
| Merz Pharmaceuticals, LLC | $126.60 | 2022 | |
| Allergan, INC. | $126.54 | 2019 | |
| Relievant Medsystems, INC. | $107.95 | 2020 | |
| Medtronic, INC. | $68.44 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $68.20 | 2025 | Senza |
| Valinor Pharma, LLC | $56.98 | 2023-2024 | Movantik |
| Foundation Fusion Solutions, LLC | $44.69 | 2023 | |
| Averitas Pharma INC. | $29.38 | 2023 | Qutenza |
| Bioventus LLC | $28.48 | 2025 | Xcell |
| Spinal Simplicity, LLC | $21.88 | 2025 | Ha Minuteman G3-R |
| Avanos Medical | $19.12 | 2024 | Generator |
| Tonix Medicines, INC. | $18.43 | 2025 | Tonmya |
| Scilex Pharmaceuticals INC. | $15.13 | 2023 | Ztlido |
| Acacia Pharma INC | $15.10 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.85 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.88 | 2024 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Gilman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.